Duchenne muscular dystrophy (DMD) is a fatal and incurable muscle degenerative disorder. We identify a function of the protease urokinase plasminogen activator (uPA) in mdx mice, a mouse model of DMD. The expression of uPA is induced in mdx dystrophic muscle, and the genetic loss of uPA in mdx mice exacerbated muscle dystrophy and reduced muscular function. Bone marrow (BM) transplantation experiments revealed a critical function for BM-derived uPA in mdx muscle repair via three mechanisms: (1) by promoting the infiltration of BM-derived inflammatory cells; (2) by preventing the excessive deposition of fibrin; and (3) by promoting myoblast migration. Interestingly, genetic loss of the uPA receptor in mdx mice did not exacerbate muscular dystrophy in mdx mice, suggesting that uPA exerts its effects independently of its receptor. These findings underscore the importance of uPA in muscular dystrophy.
Skip Nav Destination
Article navigation
10 September 2007
Article Contents
Article|
September 04 2007
uPA deficiency exacerbates muscular dystrophy in MDX mice
Mònica Suelves,
Mònica Suelves
1Program on Differentiation and Cancer and
Search for other works by this author on:
Berta Vidal,
Berta Vidal
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Search for other works by this author on:
Antonio L. Serrano,
Antonio L. Serrano
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Search for other works by this author on:
Marc Tjwa,
Marc Tjwa
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Search for other works by this author on:
Josep Roma,
Josep Roma
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Search for other works by this author on:
Roser López-Alemany,
Roser López-Alemany
8Institut d'Investigació Biomèdica de Bellvitge, E-08907 Barcelona, Spain
Search for other works by this author on:
Aernout Luttun,
Aernout Luttun
5Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven B-3000, Belgium
Search for other works by this author on:
María Martínez de Lagrán,
María Martínez de Lagrán
2Program on Genes and Disease, Center for Genomic Regulation, E-08003 Barcelona, Spain
6Centro de Investigación Biomédica en Red de Enfermedades Raras, E-08003 Barcelona, Spain
Search for other works by this author on:
Maria Àngels Díaz,
Maria Àngels Díaz
8Institut d'Investigació Biomèdica de Bellvitge, E-08907 Barcelona, Spain
Search for other works by this author on:
Mercè Jardí,
Mercè Jardí
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Search for other works by this author on:
Manuel Roig,
Manuel Roig
7Grup de Recerca de Malalties Neuro-metabòliques, Hospital Universitari Vall d'Hebron, E-08035 Barcelona, Spain
Search for other works by this author on:
Mara Dierssen,
Mara Dierssen
2Program on Genes and Disease, Center for Genomic Regulation, E-08003 Barcelona, Spain
6Centro de Investigación Biomédica en Red de Enfermedades Raras, E-08003 Barcelona, Spain
Search for other works by this author on:
Mieke Dewerchin,
Mieke Dewerchin
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Search for other works by this author on:
Peter Carmeliet,
Peter Carmeliet
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Search for other works by this author on:
Pura Muñoz-Cánoves
Pura Muñoz-Cánoves
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Search for other works by this author on:
Mònica Suelves
1Program on Differentiation and Cancer and
Berta Vidal
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Antonio L. Serrano
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Marc Tjwa
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Josep Roma
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Roser López-Alemany
8Institut d'Investigació Biomèdica de Bellvitge, E-08907 Barcelona, Spain
Aernout Luttun
5Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven B-3000, Belgium
María Martínez de Lagrán
2Program on Genes and Disease, Center for Genomic Regulation, E-08003 Barcelona, Spain
6Centro de Investigación Biomédica en Red de Enfermedades Raras, E-08003 Barcelona, Spain
Maria Àngels Díaz
8Institut d'Investigació Biomèdica de Bellvitge, E-08907 Barcelona, Spain
Mercè Jardí
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Manuel Roig
7Grup de Recerca de Malalties Neuro-metabòliques, Hospital Universitari Vall d'Hebron, E-08035 Barcelona, Spain
Mara Dierssen
2Program on Genes and Disease, Center for Genomic Regulation, E-08003 Barcelona, Spain
6Centro de Investigación Biomédica en Red de Enfermedades Raras, E-08003 Barcelona, Spain
Mieke Dewerchin
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Peter Carmeliet
4Center for Transgene Technology and Gene Therapy, Flanders Institute for Biotechnology, and
Pura Muñoz-Cánoves
1Program on Differentiation and Cancer and
3Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, E-08003 Barcelona, Spain
Correspondence to Pura Muñoz-Cánoves: [email protected]
Abbreviations used in this paper: BM, bone marrow; CK, creatine kinase; CTX, cardiotoxin; DMD, Duchenne muscular dystrophy; HE, hematoxylin/eosin; HGF, hepatocyte growth factor; SC, satellite cell; SF, scatter factor; uPA, urokinase plasminogen activator; uPAR, uPA receptor; WT, wild type.
Received:
May 22 2007
Accepted:
August 10 2007
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2007
J Cell Biol (2007) 178 (6): 1039–1051.
Article history
Received:
May 22 2007
Accepted:
August 10 2007
Connected Content
This article has been corrected
uPA deficiency exacerbates muscular dystrophy in MDX mice
Citation
Mònica Suelves, Berta Vidal, Antonio L. Serrano, Marc Tjwa, Josep Roma, Roser López-Alemany, Aernout Luttun, María Martínez de Lagrán, Maria Àngels Díaz, Mercè Jardí, Manuel Roig, Mara Dierssen, Mieke Dewerchin, Peter Carmeliet, Pura Muñoz-Cánoves; uPA deficiency exacerbates muscular dystrophy in MDX mice . J Cell Biol 10 September 2007; 178 (6): 1039–1051. doi: https://doi.org/10.1083/jcb.200705127
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Connected Content
Advertisement
